Copyright
©2011 Baishideng Publishing Group Co.
World J Hepatol. May 27, 2011; 3(5): 99-107
Published online May 27, 2011. doi: 10.4254/wjh.v3.i5.99
Published online May 27, 2011. doi: 10.4254/wjh.v3.i5.99
Anti-diabetic agent | Subjects | Outcome | Reference |
Exogenous insulin or sulphonylurea | Patients with liver cirrhosis or HCC | Increased HCC risk | [100] |
Exogenous insulin or sulphonylurea | Patients with chronic hepatitis C | Increased HCC risk | [101] |
Exogenous insulin | Chronic viral hepatitis patients who had undergone curative resection for HCC | Increased risk of HCC recurrence | [102] |
Metformin | Treatment-naïve female patients with HCV genotype 1-related chronic hepatitis and insulin resistance | Increased SVR rate | [16] |
Metformin | Patients diabetes mellitus and liver cirrhosis or HCC | Decreased HCC risk | [101] |
Metformin | Patients with liver cirrhosis or HCC | Decreased HCC risk | [112] |
Pioglitazone | Chronic hepatitis C patients who had previously failed to respond to antiviral therapy | No increase in EVR rate | [115] |
Pioglitazone | Treatment-naïve chronic hepatitis C patients with insulin resistance | Increased SVR rate | [116] |
- Citation: Kawaguchi T, Taniguchi E, Itou M, Sakata M, Sumie S, Sata M. Insulin resistance and chronic liver disease. World J Hepatol 2011; 3(5): 99-107
- URL: https://www.wjgnet.com/1948-5182/full/v3/i5/99.htm
- DOI: https://dx.doi.org/10.4254/wjh.v3.i5.99